HFA Premium Access

Management of co-morbidities in heart failure - Exploring new frontiers

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Miscellaneous
Session type: Satellite Symposium
Sponsored by Bayer AG
Date: 30 April 2017
Time: 12:45 - 14:00

Congress Session

6 presentations in this session

Introduction & remarks.

Speaker: Professor N. Danchin (Paris, FR)
Thumbnail

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Speaker: Professor M. Cowie (London, GB)
Thumbnail

Options in thrombosis prevention and vascular health – What’s on the horizon?

Speaker: Professor K. Fox (Edinburgh, GB)
Thumbnail

Broadening the evidence base for rivaroxaban in heart failure.

Speaker: Professor B. Greenberg (San Diego, US)
Thumbnail

Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

Speaker: Doctor R. Mentz (Durham, US)
Thumbnail

Q&A and closing remarks.

Speaker: Professor M. Cowie (London, GB)
Thumbnail

6 speakers from this session

Professor Nicolas Danchin

European Hospital Georges Pompidou, Paris (France)
13 presentations
0 follower

Professor Martin Cowie

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)
93 presentations
5 followers

Professor Keith Fox

University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)
36 presentations
0 follower

Professor Barry Greenberg

University of California San Diego, San Diego (United States of America)
1 presentation
0 follower

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)
2 presentations
0 follower

Professor Martin Cowie

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)
93 presentations
5 followers

This platform is supported by

logo Novo Nordisk